Vanguard Group Inc Intellia Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.37 Trillion
- Q1 2025
A detailed history of Vanguard Group Inc transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 10,752,031 shares of NTLA stock, worth $73.9 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,752,031
Previous 10,190,053
5.51%
Holding current value
$73.9 Million
Previous $119 Million
35.66%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding NTLA
# of Institutions
344Shares Held
98.4MCall Options Held
784KPut Options Held
713K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl13MShares$89.4 Million1.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$65.9 Million0.0% of portfolio
-
State Street Corp Boston, MA4.51MShares$31 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.8MShares$26.1 Million0.0% of portfolio
-
Capital International Investors Los Angeles, CA3.78MShares$26 Million0.01% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $522M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...